Patents Assigned to Gilead Science, Inc.
-
Patent number: 12377100Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.Type: GrantFiled: December 2, 2021Date of Patent: August 5, 2025Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki
-
Patent number: 12364751Abstract: Provided are HBV immunogenic polypeptides, polynucleotides encoding such polypeptides, vectors expressing such immunogenic polypeptides for use in eliciting an immune response against HBV; pharmaceutical and immunogenic compositions and kits comprising such polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HBV.Type: GrantFiled: June 15, 2023Date of Patent: July 22, 2025Assignee: Gilead Sciences, Inc.Inventors: Scott J. Balsitis, Sarah M. Ahmadi-Erber, Timo Schippers, Sarah Schmidt
-
Patent number: 12358903Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.Type: GrantFiled: January 11, 2022Date of Patent: July 15, 2025Assignee: Gilead Sciences, Inc.Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
-
Patent number: 12358887Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.Type: GrantFiled: March 15, 2023Date of Patent: July 15, 2025Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
-
Patent number: 12357577Abstract: Pharmaceutical formulations, particularly solid oral dosage forms (e.g., tablets) comprising (i) the compound of Formula I in an amount of about 40 wt % to about 70 wt %, (ii) a filler, (iii) a disintegrating agent, (iv) and a lubricant are disclosed, as are uses thereof.Type: GrantFiled: February 2, 2024Date of Patent: July 15, 2025Assignee: Gilead Sciences, Inc.Inventors: Kimberly T. Barrett, Elaine Bunyan
-
Patent number: 12338278Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.Type: GrantFiled: October 7, 2021Date of Patent: June 24, 2025Assignee: Gilead Sciences, Inc.Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Craig S. Pace, Doug Rehder, Matthew R. Schenauer, Loredana Serafini, Heather T. Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
-
Patent number: 12338233Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: December 1, 2022Date of Patent: June 24, 2025Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Patent number: 12297226Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: January 11, 2024Date of Patent: May 13, 2025Assignee: Gilead Sciences, Inc.Inventors: Elaine Bunyan, Byoung-Kwon Chun, Kassibla E. Dempah, Hon C Hui, Rao V. Kalla, Richard L. Mackman
-
Patent number: 12269812Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: July 8, 2020Date of Patent: April 8, 2025Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Patent number: 12264173Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.Type: GrantFiled: July 18, 2023Date of Patent: April 1, 2025Assignee: Gilead Sciences, Inc.Inventors: Gregory F. Chin, Byoung-Kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Dustin S. Siegel, Hai Yang
-
Patent number: 12258346Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: December 18, 2023Date of Patent: March 25, 2025Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A Codelli, John H. Conway, Jennifer L Cosman Ellis, Rao V. Kalla, Zachary A Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Patent number: 12240862Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.Type: GrantFiled: December 21, 2021Date of Patent: March 4, 2025Assignee: Gilead Sciences, Inc.Inventors: Daniel H. Byun, Eda Y. Canales, Laurent P. Debien, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Stephane Perreault, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen, Lianhong Xu
-
Patent number: 12227520Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 28, 2022Date of Patent: February 18, 2025Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
-
Patent number: 12208110Abstract: The present disclosure relates to compounds of Formula I, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for treatment of viral infections, for example for treatment of paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae infections.Type: GrantFiled: October 15, 2021Date of Patent: January 28, 2025Assignee: Gilead Sciences, Inc.Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
-
Patent number: 12202849Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.Type: GrantFiled: August 11, 2022Date of Patent: January 21, 2025Assignee: Gilead Sciences, Inc.Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
-
Patent number: 12202842Abstract: The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.Type: GrantFiled: March 9, 2023Date of Patent: January 21, 2025Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, Qingming Zhu
-
Patent number: 12202782Abstract: The present disclosure relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, for use in the treatment of cancers.Type: GrantFiled: November 17, 2021Date of Patent: January 21, 2025Assignee: Gilead Sciences, Inc.Inventors: Darryl D. Dixon, Michael A. Ischay, Trevor C. Johnson, Jeffrey E. Merit, Christopher S. Regens, Eric A. Standley, Dietrich P. Steinhuebel
-
Patent number: 12195524Abstract: Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.Type: GrantFiled: August 23, 2021Date of Patent: January 14, 2025Assignee: Gilead Sciences, Inc.Inventors: Manuel Baca, Brian A. Carr, Sheila B. Clancy, Craig S. Pace, Heather T. Stephenson, Nathan D. Thomsen
-
Patent number: 12187734Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.Type: GrantFiled: December 22, 2023Date of Patent: January 7, 2025Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
-
Patent number: D1086890Type: GrantFiled: January 30, 2025Date of Patent: August 5, 2025Assignee: Gilead Sciences, Inc.Inventors: Robert Bridges, Joseph Cordova, Gaurav Dabholkar, Alexandra Fideler, Monica Vazirani
